Cargando…
Negative p53/Positive p21 Immunostaining Is a Predictor of Favorable Response to Chemotherapy in Patients with Locally Advanced Bladder Cancer
The relationship between clinical response to DNA‐damaging drugs and p53 and p21 status in patients with locally advanced transitional cell carcinoma (TCC) of the bladder was assessed. The response to intraarterial chemotherapy (IAC) comprising 100 mg/m(2) of cisplatin (CDDP) and 40 mg/m(2) of pirar...
Autores principales: | Koga, Fumitaka, Kitahara, Satoshi, Arai, Kyoko, Honda, Mikihiko, Sumi, Shuhei, Yoshida, Ken‐ichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926463/ https://www.ncbi.nlm.nih.gov/pubmed/10804290 http://dx.doi.org/10.1111/j.1349-7006.2000.tb00961.x |
Ejemplares similares
-
The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder
por: Ibrahim, N, et al.
Publicado: (2009) -
The relationship of p53 immunostaining to survival in carcinoma of the lung.
por: McLaren, R., et al.
Publicado: (1992) -
p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations
por: Sung, You-Na, et al.
Publicado: (2022) -
Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996) -
Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer
por: Kamoshida, S, et al.
Publicado: (2007)